The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Regulatory News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Further Regarding General Meeting

2 Sep 2014 07:00

RNS Number : 5692Q
Plethora Solutions Holdings PLC
02 September 2014
 



 

 

2 September 2014

 

Plethora Solutions Holdings PLC

("Plethora" or the "Company")

 

Further Regarding General Meeting

 

 

Further to the announcement made on 29 August 2014, Plethora Solutions Holdings plc (AIM: PLE) announces that the Company has posted a new Notice of General Meeting to Shareholders, which is intended to be in substitution for that attached to the Circular letter dated 29 August 2014. The new Notice of General Meeting to Shareholders will be made available on the Company's website, www.plethorasolutions.co.uk.

 

Shareholders are advised to disregard the Notice of General Meeting, and accompanying proxy card, attached to the Circular Letter dated 29 August 2014. It is the intention of the Board that a resolution will be put to the meeting of shareholders already scheduled for 17 September 2014 pursuant to the notice dated 29 August 2014 resolving that the meeting will be adjourned sine die. Please note that the date of the replacement General Meeting has changed to 18 September 2014.

 

Shareholders will receive a new Notice of General Meeting and a replacement Form of Proxy for use at the replacement General Meeting to be held on 18 September 2014.

 

All terms defined in that letter dated Friday, 29 August 2014 have the same meaning when used in this announcement. Shareholders and investors should read the whole text of this announcement.

 

 

Background

 

The Chairman of the Company wrote to Shareholders on Friday, 29 August 2014 in order, inter alia, to convene a General Meeting of shareholders to pass the necessary shareholders resolutions to approve the matters referred to in that Circular letter.

 

Unfortunately, the Notice of General Meeting attached to that Circular letter contained some minor printing errors. Because the Notice of General Meeting is a formal document, it is necessary to issue a new Notice of General Meeting intended to be in substitution for that attached to the Circular letter dated 29 August 2014.

 

Accordingly, a new Notice of General Meeting in which the printing errors have been corrected together with a replacement proxy card for use in relation to the Notice of General Meeting has been sent to Shareholders.

 

Shareholders are advised to disregard the Notice of General Meeting, and accompanying proxy card, attached to the Circular Letter dated 29 August 2014. It is the intention of the Board that a resolution will be put to the meeting of shareholders already scheduled for 17 September 2014 pursuant to the notice dated 29 August 2014 resolving that the meeting will be adjourned sine die.

 

Please note that the date of the replacement General Meeting has changed to 18 September 2014.

 

 

Action to be Taken

 

Shareholders will receive a new Notice of General Meeting and a replacement Form of Proxy for use at the replacement General Meeting. Whether or not Shareholders intend to attend the replacement General Meeting Shareholders are requested to complete the replacement Form of Proxy in accordance with the instructions printed on it and to return it to the Company's registrars, Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, as soon as possible, and in any event so as to arrive no later than 10:00am on 16 September 2014.

 

If Shareholders hold their Ordinary Shares in CREST they may appoint a proxy using the CREST proxy appointment service by following the instructions in note (6) to the replacement Notice of General Meeting. The completion and return of a Form of Proxy, or the electronic appointment of a proxy will not preclude Shareholders from attending the General Meeting and voting in person should they so wish.

 

 

Recommendation

 

The Directors believe that the Placing & Subscription, and therefore the Resolutions set out in the replacement Notice of General Meeting, are in the best interests of the Company and Shareholders taken as a whole. The Directors unanimously recommend that Shareholders vote in favour of those Resolutions, as they intend to do in respect of their own shareholdings, which in aggregate total 131,949,742 Ordinary Shares representing approximately 31.8% of the existing issued ordinary share capital of the Company.

 

-Ends-

 

Enquiries:

Plethora Solutions

Jim Mellon, Chairman

Jamie Gibson, CEO

Mike Wyllie, CSO

Mike Collis, CFO

Greg Bailey, NXD

 

Tel : +44(0) 20 3077 5400

Daniel Stewart (Nomad & Joint Broker)

Emma Earl / Alex Brearley (Nomad)

Martin Lampshire (Broker)

 

Tel : +44(0) 20 7776 6550

 

Hybridan LLP (Joint Broker)

Claire Louise Noyce

William Lynne

Niall Pearson

 

Tel: +44(0) 20 3713 4581

Tel: +44(0) 20 3713 4582

Tel: +44(0) 20 3713 4583

 

Britton Financial PR

Tim Blackstone

Tel: + 44 (0) 20 7242 9786

+44 (0) 7957 140416

 

About Plethora:

 

Plethora is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L). Further information is available at www.plethorasolutions.co.uk

Plethora is focussed on seeking to launch PSD502™ for the treatment of premature ejaculation.

 

About PSD502™ & Premature Ejaculation:

 

PSD502™ is a topical spray for the treatment of premature ejaculation containing lidocaine and prilocaine in a eutectic-like mixture. Premature ejaculation is possibly the most common form of sexual dysfunction in men. Epidemiological studies conducted in the US and in Europe indicate a prevalence of 20 - 30% in men of all ages. There is currently no globally approved and effective pharmaceutical treatment for this condition.

 

In the absence of any widely approved pharmaceutical therapy with good patient acceptance, the premature ejaculation market offers significant potential for development and growth. An effective drug therapy for premature ejaculation may have a comparable commercial potential to the erectile dysfunction drugs.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FURUAOURSVAKRUR
Date   Source Headline
18th Nov 20154:56 pmBUSForm 8.3 - Plethora Solutions Holdings Plc
18th Nov 20158:08 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
17th Nov 20159:00 amRNSForm 8 (OPD) Plethora Solutions Holdings PLC
17th Nov 20159:00 amRNSForm 8 (OPD) (Regent Pacific Group Limited)
17th Nov 20159:00 amRNSForm 8 (OPD) (Plethora Solutions Holdings plc)
17th Nov 20158:09 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
16th Nov 20158:47 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
13th Nov 20158:59 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
12th Nov 20155:26 pmRNSUpdate in relation to Letters of Intent
12th Nov 20159:03 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
11th Nov 20153:14 pmRNSForm 8.3 - AMENDMENT Plethora Solutions Holdings
11th Nov 201510:54 amRNSForm 8.3 - Plethora Solutions Holdings PLC
11th Nov 20157:41 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
10th Nov 20158:32 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
10th Nov 20158:15 amRNSLetter of Intent Signed
9th Nov 20155:10 pmRNSHolding(s) in Company
9th Nov 20152:36 pmRNSForm 8.3 - Plethora Solutions Holdings Plc
9th Nov 201511:50 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
6th Nov 20153:20 pmRNSRULE 2.10 UPDATE
6th Nov 20159:14 amRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
5th Nov 20153:53 pmRNSForm 8.3 - Plethora Solutions Holdings Plc
5th Nov 20151:14 pmRNSForm 8.5 (EPT/RI) - Plethora Solutions PLC
5th Nov 20158:27 amRNSForm 8.3 - Regent Pacific Group Ltd
4th Nov 20156:28 pmRNSRULE 2.10 UPDATE
4th Nov 20154:35 pmRNSForm 8 (DD) - Plethora Solutions Holdings plc
4th Nov 201510:03 amRNSPossible Offer for Plethora Solutions Holdings plc
28th Oct 20152:21 pmRNSDirector's Shareholding
28th Aug 20154:21 pmRNSHalf Yearly Report
11th Jun 201512:00 pmRNSResult of AGM
5th Jun 201512:16 pmRNSAgreement with Regent Pacific
12th May 20157:01 amRNSBoard Appointment
27th Apr 20154:30 pmRNSHolding(s) in Company
15th Apr 20155:05 pmRNSHolding(s) in Company
13th Apr 20158:16 amRNSHolding(s) in Company
1st Apr 20157:00 amRNSDirector Dealing and Issue of Equity
30th Mar 20151:30 pmRNSFinal Results
13th Feb 20152:33 pmRNSDirector/PDMR Dealing
9th Jan 20155:00 pmRNSTo attend J.P. Morgan's 33rd Healthcare Conference
22nd Dec 20147:00 amRNSDirector/PDMR dealing
11th Dec 20147:00 amRNSAppointment of NOMAD and Broker
11th Nov 20147:00 amRNSCompany Update
10th Nov 20147:00 amRNSRecordati Upfront Payment Received
31st Oct 20147:00 amRNSChange of Adviser
7th Oct 20147:00 amRNSPSD502 to be marketed as Fortacin in the EU
3rd Oct 201411:11 amRNSHolding(s) in Company
30th Sep 20145:38 pmRNSTotal Voting Rights
29th Sep 20142:26 pmRNSIssue of Equity
29th Sep 20147:00 amRNSUpdate regarding the European License Agreement
23rd Sep 20145:28 pmRNSHolding(s) in Company
19th Sep 20142:25 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.